免疫检查点阻断通过扩增效应 CD8⁺ T 细胞克隆增强淋巴细胞清除性化疗诱导的抗肿瘤免疫
Immune Checkpoint Blockade Augments Lymphodepleting Chemotherapy-Induced Antitumor Immunity by Expanding Effector CD8+ T-cell Clones.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
TIL（肿瘤浸润淋巴细胞）在鼻腔鼻窦黏膜黑色素瘤中的预后价值
英文原题：Prognostic Value of Tumor-Infiltrating Lymphocytes in Sinonasal Mucosal Melanoma.
查看英文原题
Prognostic Value of Tumor-Infiltrating Lymphocytes in Sinonasal Mucosal Melanoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
研究概要
我们的结果表明，TIL 密度是 SNMM 患者获得更好生存的强预后因素。
中文摘要
方法
回顾性分析27例原发SNMM患者的病史和组织学标本，确定TIL分级，并分析TIL与AJCC肿瘤分期、总生存期及无复发生存期之间的关联。
结果
原发肿瘤中TIL浸润旺盛或非旺盛的患者，生存时间显著长于无淋巴细胞浸润的SNMM患者。TIL旺盛与较低的T3分期以及无复发生存和5年生存改善相关。
结论
结果表明，TIL密度是SNMM患者较好生存结局的强预后因素。仍需开展样本量更大的前瞻性研究，以确定未来是否应将TIL纳入AJCC分期指南。证据等级：3级。
展开英文摘要原文
METHODS
Patient history and histologic specimens from 27 patients with primary SNMM were retrospectively analyzed. TIL grade was determined and associations between TILs and AJCC tumor stage, overall survival, and recurrence-free survival were analyzed.
RESULTS
Patients with TILs in the primary tumor classified as brisk or non-brisk survived significantly longer than patients with SNMMs lacking lymphocyte infiltrates. Brisk TILs were associated with the lower T3 stage and increased recurrence-free and 5-year survival.
CONCLUSION
Our results indicate that TIL density is a strong prognostic factor for better survival in SNMM. Prospective studies with larger case numbers are warranted to determine whether TILs should be included in future AJCC staging guidelines. LEVEL OF EVIDENCE: 3 Laryngoscope, 132:1334-1339, 2022.
论文信息
- 作者
- Ledderose S、Ledderose C、Penkava J、Ledderose GJ
- 第一作者单位
- Department of Pathology, Ludwig Maximilian University of Munich, Munich, Germany.Germany
- 通讯作者单位
- Department of Otorhinolaryngology, Head and Neck Surgery, Ludwig Maximilian University of Munich, Munich, Germany.Germany
- 期刊
- The Laryngoscope2022 Jul
- 原文标识
- PubMed 34415055 · DOI 10.1002/lary.29820